Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Keurig Dr Pepper Down Nearly 6%, on Pace for Largest Percent Decrease Since October 2025 -- Data Talk

Keurig Dr Pepper Down Nearly 6%, on Pace for Largest Percent Decrease Since October 2025 -- Data Talk

Dow JonesDow Jones2026/11/03 14:59

Keurig Dr Pepper Inc. (KDP) is currently at $34.67, down $2.15 or 5.83%

--Would be lowest close since Oct. 21, 2026, when it closed at $34.47

--On pace for largest percent decrease since Oct. 29, 2025, when it fell 5.89%

--Snaps a four day winning streak

--Up 23.8% year-to-date; on pace for best year since 2018, when it rose 64.07%

--Down 13.49% from its all-time closing high of $40.08 on Aug. 16, 2022

--Up 31.05% from 52 weeks ago (Nov. 4, 2025), when it closed at $26.46

--Down 5.83% from its 52-week closing high of $36.82 on Nov. 2, 2026

--Up 37% from its 52-week closing low of $25.31 on April 2, 2026

--Traded as low as $34.61

--Down 6% at today's intraday low; largest intraday percent decrease since Oct. 29, 2025, when it fell as much as 6.1%

--Fourth worst performer in the S&P 500 today

--Third worst performer in the Nasdaq 100 today

All data as of 9:56:42 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

November 03, 2026 09:59 ET (14:59 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss